Table 1.
CD4-binding-site antibodies that effectively neutralize HIV-1.
| Antibody type |
Representative mAb |
Donor | IGHV | IGK/LV | CDR H3 length |
CDR L3 length |
Maturation* (HV/LV, %) |
Breadth* (%) |
Potency# (μg/mi) |
Identification% | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Canonical CDR H3-utilizer | b12 | ND | 1-3*01 | 3-20*01 | 18 | 9 | 13/13 | 45 | 9.0 | Phage | [29] |
| HJ16 | 242315 | 3-30*18 | 4-1*01 | 19 | 8 | 28/20 | 30 | 12.8 | EBV | [23] | |
| CH103 | CHAVI 505 | 4-61*01 | 3-1*01 | 13 | 10 | 16/12 | 54 | 13.8 | RSC3-probe | [30]•• | |
| VH1-2-derived VRC01 class | VRC01 | NIAID 45 | 1-2*02 | 3-20*01 | 12 | 5 | 32/39 | 89 | 0.5 | RSC3-probe | [24] |
| VRC-PG04 | IAVI 74 | 1-2*02 | 3-20*01 | 14 | 5 | 30/19 | 78 | 0.8 | RSC3-probe | [6] | |
| VRC-CH31 | CHAVI 0219 | 1-2*02 | 1-33*01 | 13 | 5 | 23/15 | 81 | 0.6 | RSC3-probe | [6] | |
| VRC-PG20 | IAVI 23 | 1-2*02 | L2-14*01 | 13 | 5 | 24/15 | 77 | 0.8 | RSC3-probe | [26]•• | |
| 3BNC117 | RU 3 | 1-2*02 | 1-33*01 | 10 | 5 | 27/17 | 84 | 0.4 | 2CC-probe | [25] | |
| 12A12 | IAVI 57 | 1-2*02 | 1-33*01 | 13 | 5 | 22/18 | 82 | 0.1 | 2CC-probe | [25] | |
| VRC23 | 127/C | 1-2*02 | 3-15*01 | 12 | 5 | 21/14 | 65 | 7.4 | RSC3-probe | [19]•• | |
| VH1-46-derived | 1B2530 | RU1 | 1-46*02 | 1-47 | 16 | 11 | 27/16 | 42 | 12.3 | 2CC-probe | [25] |
| 8ANC131 | RU8 | 1-46*02 | 3-11 | 16 | 9 | 26/19 | 77 | 4.1 | 2CC-probe | [25] | |
*
Affinity maturation rates of both heavy chain and light chain variable domains are calculated on IgBLAST based on nucleotide sequences except those for antibodies b12 which were calculated with amino acid sequences.
#
Average potency values are based on IC50 values with breadth defined at a maximum of 50μg/ml as reported in cited references or [19]••.
%
“Phage” refers to phage display,“ EBV” to Epstein-Barr virus immortalization, and “RSC3-probe” and“ 2CC-probe” to the different probes used in B cell selection.